Đang chuẩn bị liên kết để tải về tài liệu:
The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: A systematic review

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Although acute oxaliplatin-induced neuropathy (OXIPN) is frequently regarded to be transient, recent studies have reported prolongation of infusion times, dose reduction and treatment cessation following the first dose of oxaliplatin in quarter of patients. | The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle A systematic review

TÀI LIỆU LIÊN QUAN

The association of megalin and cubilin genetic variants with serum levels of 25-hydroxvitamin D and the incidence of acute coronary syndrome in Egyptians: A case control study

The incidence, risk factors and prognosis of acute kidney injury in severe and critically ill patients with COVID-19 in mainland China: A retrospective study

The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: A systematic review

Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia

A geospatiotemporal and causal inference epidemiological exploration of substance and cannabinoid exposure as drivers of rising US pediatric cancer rates

Low incidence of ABL-class and JAK-STAT signaling pathway alterations in uniformly treated pediatric and adult B-cell acute lymphoblastic leukemia patients using MRD risk-directed approach – a populationbased study

A systematic review of the incidence, risk factors and prognosis of acute exacerbation of systemic autoimmune disease-associated interstitial lung disease

Impact of goal-directed hemodynamic management on the incidence of acute kidney injury in patients undergoing partial nephrectomy: A pilot randomized controlled trial

TNF-α - mediated peripheral and central inflammation are associated with increased incidence of PND in acute postoperative pain

Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: Incidence and risk factors from real-world experience
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.